Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Raymond James to Moderate Buy Rating

by · The Markets Daily

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) was upgraded by analysts at Raymond James to a “moderate buy” rating in a report issued on Thursday,Zacks.com reports.

PBH has been the topic of several other research reports. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Wednesday. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Finally, DA Davidson reissued a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Read Our Latest Stock Report on PBH

Prestige Consumer Healthcare Stock Up 0.1 %

PBH stock opened at $78.72 on Thursday. The firm has a market cap of $3.89 billion, a PE ratio of 19.15, a P/E/G ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare has a 12 month low of $57.95 and a 12 month high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The firm has a 50 day simple moving average of $79.25 and a 200 day simple moving average of $73.04.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.07 EPS. Equities research analysts forecast that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In other news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at $1,505,930. This represents a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently bought and sold shares of PBH. Franklin Resources Inc. lifted its position in shares of Prestige Consumer Healthcare by 4.3% in the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after buying an additional 894 shares during the last quarter. Sanctuary Advisors LLC lifted its holdings in Prestige Consumer Healthcare by 11.0% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock worth $1,244,000 after purchasing an additional 1,715 shares during the last quarter. Coldstream Capital Management Inc. bought a new stake in Prestige Consumer Healthcare during the third quarter worth approximately $205,000. Geode Capital Management LLC grew its holdings in Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Finally, M&T Bank Corp grew its holdings in Prestige Consumer Healthcare by 23.8% during the third quarter. M&T Bank Corp now owns 4,594 shares of the company’s stock valued at $331,000 after purchasing an additional 882 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Featured Articles